Background-The optimal revascularization strategy in patients with multivessel disease presenting with cardiogenic shock complicating ST-segment-elevation myocardial infarction remains unknown. 
C ardiogenic shock occurs in 6% to 12% of patients with ST-segment-elevation myocardial infarction (STEMI) and is associated with increased mortality. [1] [2] [3] The SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) demonstrated improved short-and long-term survival with early revascularization in patients with acute myocardial infarction (MI) and cardiogenic shock. 4, 5 However, despite the increasing use of percutaneous coronary intervention (PCI) in these patients, mortality remains high at 40% to 50%. 2 
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Multivessel coronary artery disease is present in ≤80% of patients with cardiogenic shock complicating STEMI and is associated with worse outcomes. 4, 6 Recent data from randomized controlled trials (RCTs) have shown that in patients with STEMI without cardiogenic shock, multivessel PCI (MV-PCI) compared with culprit vessel-only PCI (CO-PCI) is associated with improved clinical outcomes, but mainly driven by less repeat revascularization. [7] [8] [9] [10] However, no randomized data exist on MV-PCI versus CO-PCI in patients with cardiogenic shock. The 2013 American College of Cardiology Foundation/American Heart Association guidelines for the management of STEMI suggests that in patients with cardiogenic shock because of pump failure, PCI of a severe stenosis in a large noninfarct artery might improve hemodynamic stability and should be considered during the primary procedure. 11 Similarly, the 2014 European Society of Cardiology/ European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization state that multivessel PCI during STEMI should be considered in patients with cardiogenic shock in the presence of multiple, critical stenoses or highly unstable lesions (angiographic signs of possible thrombus or lesion disruption), and if there is persistent ischemia after PCI on the supposed culprit lesion. 12 These recommendations are largely based on theoretical considerations and extrapolation of clinical trial data in hemodynamically stable STEMI patients, but not on nonrandomized studies in patients with cardiogenic shock. However, observational studies comparing MV-PCI versus CO-PCI in patients with cardiogenic shock have produced conflicting results, and the optimal revascularization strategy in these patients remains unknown. 1, 6, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In addition, several observational studies have included patients with STEMI and non-STEMI, and evidence suggests that clinical profile, treatment, and outcomes are different in these 2 groups of patients. 1, 3, 6, 15, 16, 22 Furthermore, prior meta-analyses comparing MV-PCI versus CO-PCI have included studies in patients with or without shock. 23, 24 Hence, the primary objective of our study was to perform a systematic review and metaanalysis of studies comparing clinical outcomes of MV-PCI versus CO-PCI specifically in patients with cardiogenic shock complicating STEMI.
Methods

Data Sources
We searched PubMed, MEDLINE (Medical Literature Analysis and Retrieval System Online), CINHAL (Cumulative Index to Nursing and Allied Health Literature), Cochrane CENTRAL (Central Register of Controlled Trials), EMBASE (Excerpta Medica Database), Web of Science, and Google Scholar from August 1999 (publication of the pivotal SHOCK trial which demonstrated improved survival with early revascularization in patients with acute MI and cardiogenic shock) through October 2016 for English language, peer-reviewed publications. Conference proceedings for the Scientific Sessions of the American College of Cardiology, American Heart Association, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics, and EuroPCR (Congress of the European Association of Percutaneous Cardiovascular Interventions) were also searched. The following key words and Medical Subject Headings (MeSH) terms were used: cardiogenic shock, shock, cardiogenic (MeSH), myocardial infarction (MeSH), percutaneous coronary intervention (MeSH), percutaneous transluminal coronary angioplasty (MeSH), myocardial revascularization (MeSH), multivessel, multi-vessel, culprit vessel, culprit-only, non-infarct, and complete revascularization. Reference lists of review articles, meta-analyses, and original studies identified by the electronic search were reviewed to find other potentially eligible studies. Authors of studies were contacted when results were unclear, relevant data were not reported, or additional data were needed. 1, 6, 13, [15] [16] [17] [18] 20, 22 
Study Selection
Eligible studies had to fulfill the following criteria for inclusion in the meta-analysis: (1) study (sub)group included patients with STEMI, multivessel disease (MVD), and cardiogenic shock, (2) compared CO-PCI versus immediate/single-stage MV-PCI, (3) included at least 10 patients in each treatment group, (4) >50% of the patients underwent stent placement, and (5) at least in-hospital/30-day mortality data (number of events or event rates) for the 2 treatment groups were reported or provided by the authors on request. Because there are no randomized
WHAT IS KNOWN
• Recent data from randomized controlled trials have shown that in patients with ST-segment-elevation myocardial infarction without cardiogenic shock, multivessel percutaneous coronary intervention (MV-PCI) compared with culprit vessel-only PCI is associated with improved clinical outcomes, but mainly driven by less repeat revascularization.
• No randomized data exist on MV-PCI versus culprit vessel-only PCI in patients with cardiogenic shock, and observational studies have produced conflicting results.
WHAT THE STUDY ADDS
• In this meta-analysis of 11 nonrandomized studies including 5850 patients with multivessel disease, ST-segment-elevation myocardial infarction, and cardiogenic shock, there were no significant differences in short-term mortality, long-term mortality, cardiovascular death, reinfarction, or repeat revascularization with immediate/single-stage MV-PCI versus culprit vessel-only PCI.
• There was a nonsignificant trend toward higher inhospital stroke and renal failure, but no difference in major bleeding with MV-PCI compared with culprit vessel-only PCI.
• Given the limitations of observational data, randomized trials are needed to determine the role of MV-PCI in patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction. studies comparing MV-PCI versus CO-PCI in patients with STEMI and cardiogenic shock, only nonrandomized studies and post hoc analyses of RCTs were included in this meta-analysis. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-Analysis of Observational Studies in Epidemiology) checklists for the protocol of our meta-analysis. 25 
Data Extraction and Quality Assessment
Two physician reviewers (D.K. and P.S.) independently assessed study eligibility, quality, and extracted data. Disagreements were resolved by consensus. Study quality was evaluated using the Newcastle Ottawa Scale, which assigns a star for 3 areas of study quality: selection (4 criteria), comparability (1 criterion), and outcome (3 criteria; Table I in the Data Supplement). 26 Data were extracted from eligible studies on study design, baseline clinical characteristics, procedural details, and outcomes. Propensity-matched or inverse probability weight-adjusted data were used for the outcomes when available.
End Points
The primary end point was short-term (in-hospital or 30 days) allcause mortality. Secondary end points included long-term (longest study follow-up) mortality, cardiovascular death, reinfarction, and repeat revascularization. Safety end points included in-hospital stroke, major bleeding, and renal failure.
Statistical Analysis
Random-effects models of DerSimonian and Laird were used to calculate pooled odds ratio (OR) and corresponding 95% confidence interval (CI) for each of the end points. Heterogeneity was assessed using the Higgins I 2 statistic, with values <25% and >75% considered indicative of low and high heterogeneity, respectively. Publication bias was assessed visually by asymmetry in funnel plots and formally using Egger regression test and Begg and Mazumdar rank correlation test. We performed sensitivity analysis after excluding single-center studies, studies with <50% drug-eluting stent use, and studies with <1 year follow-up. Chronological cumulative meta-analyses were performed to determine whether the effect size and precision would shift based on the changes in treatments over the course of time. Because individual studies included data over several years, the chronological order was based on the earliest year of the study period. We also conducted meta-regression analysis exploring the potential for effect modification by multiple variables including age, female sex, diabetes mellitus, chronic kidney disease, prior MI, prior coronary artery bypass grafting, left ventricular ejection fraction <40%, cardiac arrest (pre-or intraprocedure), left main/left anterior descending coronary artery as culprit vessel, stent use, drug-eluting stent use, and intra-aortic balloon pump use on the primary end point of short-term mortality. All results are for MV-PCI compared with CO-PCI. All tests were 2-tailed with a P value of <0.05 considered significant. Analyses were performed using the Review Manager Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014, Copenhagen, Denmark) and Comprehensive Meta-Analysis Version 3.0 (Biostat, Englewood, NJ).
Results
Study Selection and Description of Included Studies
The database search yielded 946 articles of which 48 full-text articles were assessed for eligibility ( Figure 1 ). Conference abstracts for which full text was not published were excluded to ensure high-quality data. Finally, 11 studies were included in the meta-analysis. The characteristics of the included studies are shown in the Table. Of the 11 studies, 6 were retrospective, 4 were prospective, and 1 was a post hoc analysis of a RCT. Of the 10 nonrandomized studies, 8 were from national, multicenter registries, and 2 were single-center studies. In majority of the studies, 1, 14, 16, 17, [19] [20] [21] [22] MVD was defined as ≥50% stenosis in ≥2 major epicardial coronary arteries, except 2 studies 6,18 which used ≥70% as the cutoff, and 2 studies 13, 15 that did not provide the exact cutoff used. The 11 studies included 5850 patients with STEMI, MVD, and cardiogenic shock. Of these, 4693 (80.2%) underwent CO-PCI and 1157 
Short-Term Mortality
All 11 studies provided data on the primary end point of short-term mortality. There was no statistically significant difference in shortterm mortality with MV-PCI compared with CO-PCI (OR, 1.08; 95% CI, 0.81-1.43; P=0.61; I 2 =67%; Figure 2 ). There was no evidence of publication bias ( Figure IA in the Data Supplement).
Secondary End Points
Event rates at 6-and 12-month follow-up were used for analyses of secondary efficacy end points. The mean duration of follow-up weighted for the sample size was 9.8 months. 6 Cavender et al, 13 Cavender et al, 14 Hambraeus et al, 15 Jaguszewski et al, 16 Mylotte et al, 18 Park et al, 19 van der Schaaf et al, 20 Yang et al, 21 Zeymer et al, 1 and Zeymer et al. 22 CI indicates confidence interval.
Figure 3.
Comparison of long-term mortality after multivessel (MV) versus culprit vessel-only (CO) percutaneous coronary intervention (PCI). Studies included in this analysis are Cavender et al, 14 Hambraeus et al, 15 Jeger et al, 17 Mylotte et al, 18 Park et al, 19 van der Schaaf et al, 20 Yang et al, 21 and Zeymer et al. 22 CI indicates confidence interval. Multivessel PCI for Cardiogenic Shock 
Sensitivity Analyses, Cumulative Meta-Analyses, and Meta-Regression
Sensitivity analyses after excluding single-center studies and studies with <50% drug-eluting stent use showed similar results for short-and long-term mortality (Table IV in 
Discussion
In this meta-analysis of nonrandomized studies of patients with cardiogenic shock complicating STEMI, we found no significant difference in short-term mortality, long-term 18 Park et al, 19 Yang et al, 21 and Zeymer et al. 22 CI indicates confidence interval.
Figure 5. Comparison of reinfarction after multivessel (MV) versus culprit vessel-only (CO) percutaneous coronary intervention (PCI).
Studies included in this analysis are Hambraeus et al, 15 Mylotte et al, 18 Park et al, 19 Yang et al, 21 and Zeymer et al. 22 CI indicates confidence interval. Multivessel PCI for Cardiogenic Shock mortality, cardiovascular death, reinfarction, or repeat revascularization with immediate/single-stage MV-PCI versus CO-PCI. There was a nonsignificant trend toward higher rates of in-hospital stroke and renal failure with MV-PCI compared with CO-PCI. To our knowledge, this is the first meta-analysis comparing MV-PCI versus CO-PCI specifically in patients with cardiogenic shock complicating STEMI.
The optimal revascularization strategy (MV-PCI versus CO-PCI) in patients with STEMI complicated by cardiogenic shock remains unknown. MV-PCI of nonculprit arteries may theoretically limit infarct size and preserve left ventricular function, both of which are associated with improved survival in patients with acute MI. 27, 28 However, in our meta-analysis, immediate MV-PCI was not associated with reduction in short-or longterm mortality in patients with cardiogenic shock complicating STEMI, compared with CO-PCI. The lack of difference may be related to the imbalance in baseline characteristics in nonrandomized studies and the fact that we were unable to adjust for patient and operator characteristics which may have influenced the choice of revascularization strategy. Because all included studies were nonrandomized, it is possible that any potential benefit of MV-PCI was lost because patients who underwent MV-PCI were sicker and therefore did worse compared with those undergoing CO-PCI. Nonetheless, even in patients with STEMI without cardiogenic shock, the PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) and CvLPRIT (Complete Versus LesionOnly Primary PCI Pilot Study) trials showed no difference in all-cause mortality with immediate MV-PCI versus CO-PCI. 7, 9 Similarly, previous pairwise and network meta-analyses of randomized and nonrandomized studies that included patients with STEMI with or without cardiogenic shock have also shown similar or higher all-cause mortality with single-stage MV-PCI versus CO-PCI, but lower short-and long-term mortality with staged MV-PCI compared with both CO-PCI and single-stage MV-PCI. 23, 29 During our literature search for the current metaanalysis, we found 5 studies which included patients with or without cardiogenic shock undergoing single-stage MV-PCI or staged MV-PCI. [30] [31] [32] [33] [34] However, these studies included few patients and did not report outcomes separately in patients with cardiogenic shock and those undergoing staged MV-PCI.
RCTs and meta-analyses of RCTs in patients with STEMI without cardiogenic shock have shown a significant reduction in repeat revascularization and a nonsignificant trend toward reduced MI with MV-PCI when compared with CO-PCI. 7, 35, 36 However, in patients with STEMI with cardiogenic shock, we found no significant difference in reinfarction or repeat revascularization with MV-PCI versus CO-PCI. The end point of repeat revascularization is influenced by the fact that 100% of patients with MV-PCI undergo additional revascularization of the noninfarct-related arteries upfront. Successful MV-PCI may prevent early and late recurrent ischemia or infarction because of the noninfarct-related lesions. On the contrary, complicated or unsuccessful PCI of the noninfarct-related artery during MV-PCI may increase the risk of periprocedural MI because of distal embolization, side-branch occlusion, coronary dissection, no-reflow, or other procedure-related factors. 37 Some of the challenges interventionalists might encounter while performing PCI in STEMI patients with cardiogenic shock may include stent undersizing because of coronary vasospasm as a result of concomitant administration of catecholamines and increased risk of thrombotic complications because of poor coronary flow. Similarly, patient-related factors including MVD, reduced left ventricular ejection fraction, and presence of systemic inflammation, all of which are common in patients with cardiogenic shock, may also increase the risk of periprocedural MI. 37 In patients with STEMI without cardiogenic shock, MV-PCI is not associated with an increased risk of stroke, contrast-induced nephropathy, or major bleeding. [7] [8] [9] 35 On the contrary, we observed a nonsignificant trend toward higher rates of in-hospital stroke and renal failure with MV-PCI compared with CO-PCI in patients with cardiogenic shock complicating STEMI. Although presentation with STEMI, use of intra-aortic 15 Mylotte et al, 18 Park et al, 19 Yang et al, 21 and Zeymer et al. 22 CI indicates confidence interval. Multivessel PCI for Cardiogenic Shock balloon pump, and use of greater contrast volumes are independent predictors of PCI-related stroke, MV-PCI is not independently associated with an increased risk of ischemic stroke. 38, 39 The nonsignificant higher stroke rate with MV-PCI in our metaanalysis may be because of selection bias, with the potential that sicker patients were more likely to undergo MV-PCI. In addition, factors associated with PCI-related stroke such as longer procedure time and number of catheter exchanges were not evaluated. Further, it is difficult to diagnose stroke clinically in this patient population as many of them also had concomitant cardiac arrest and require mechanical ventilation necessitating sedation. Presentation with STEMI and cardiogenic shock is associated with 2-to 3-fold higher risk of developing acute kidney injury after PCI. 40 This together with the use of higher amounts of contrast during MV-PCI may explain the trend toward higher rates of renal failure in this patient population.
Limitations
Given the lack of RCTs, this meta-analysis included only nonrandomized studies and had all limitations of observational data including selection bias and unmeasured confounding. In the studies included, the choice of revascularization strategy was at the operator's discretion and was likely influenced by patient and operator characteristics for which we were unable to adjust because of the lack of patient-level data. For example, the exact stenosis severity was not known, and the majority of included studies defined MVD with a cutoff of ≥50% stenosis as opposed to ≥70%, meaning that a proportion of patients classified as MVD getting CO-PCI may in fact not have had another severe stenosis. This point is especially relevant, as after the SHOCK trial publication, many operators would have felt compelled to attempt complete revascularization in patients who truly had multiple severe stenoses. In addition, the influence of shock severity on 6 Cavender et al, 13 Hambraeus et al, 15 Jaguszewski et al, 16 Park et al, 19 Yang et al, 21 Zeymer et al, 1 and Zeymer et al. 22 CI indicates confidence interval. Multivessel PCI for Cardiogenic Shock outcomes could not be determined. 41 Moderate-to-severe heterogeneity was seen for some of the end points studied. The degree of complete revascularization in the MV-PCI group was not known. Our meta-analysis addresses the question of single-stage MV-PCI versus CO-PCI but does not provide insights into staged MV-PCI as a revascularization strategy in patients with cardiogenic shock. As mentioned earlier, although we found 5 studies which included patients with or without cardiogenic shock who underwent single-stage or staged MV-PCI, none of these studies provided data separately in the subgroup of shock patients. [30] [31] [32] [33] [34] Nonetheless, it is difficult to compare CO-PCI versus staged MV-PCI in nonrandomized studies in this particular patient population without introducing substantial survival bias (sicker patients are likely to die while waiting for staged MV-PCI). Last, although this meta-analysis included 11 nonrandomized studies, 52.8% of the patients came from a single study.
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Conclusions
Notwithstanding the limitations of nonrandomized data, this carefully performed meta-analysis provides important evidence that in patients with cardiogenic shock complicating STEMI, immediate/single-stage MV-PCI may not provide additional benefit in improving short-or long-term mortality beyond that offered by successful PCI of the culprit vessel alone. Well-designed, adequately powered RCTs are needed to confirm or refute these findings and to determine the optimal revascularization strategy in this high-risk patient population. The ongoing COMPLETE (Complete versus Culprit-only Revascularization to Treat Multivessel Disease After Primary PCI for STEMI [NCT01740479]) and CULPRIT-SHOCK (Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock) trials will provide important answers. 42 The COMPLETE trial will determine whether a strategy of staged PCI of all suitable nonculprit lesions is superior to CO-PCI in reducing the composite outcome of cardiovascular death or MI in patients with MVD and STEMI. The CULPRIT-SHOCK trial will examine whether CO-PCI plus additional staged revascularization is superior to immediate/single-stage MV-PCI in reducing 30-day mortality and severe renal failure requiring renal replacement therapy in 706 acute MI (STEMI and non-STEMI) patients with cardiogenic shock and MVD. 
